According to IMS, for the 12 months ending July 2014, the US market for Ketorolac approximated $34 million. As with all products in Sagent’s portfolio, Ketorolac features Sagent’s PreventIV MeasuresSM packaging and labeling, designed to help reduce medication errors.
About Ketorolac Tromethamine Injection, USP
Ketorolac Tromethamine Injection, USP is indicated for the short-term (<=5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting.